How to Read Peptide COAs Before You Order

A peptide vial can look identical whether it contains correctly identified research material or a poorly documented substitute. The practical difference is the paperwork behind it. Knowing how to read peptide COA documentation lets you assess the evidence attached to a specific batch, rather than relying on a broad purity claim printed on a product page.

For research buyers, a Certificate of Analysis is not a marketing extra. It is a batch-level quality record. A useful COA should connect the material in your hand to a defined batch number, testing method and result. It should also give enough detail for you to identify what was tested, when it was tested and whether the reported result actually supports the supplier’s claim.

Start with batch traceability

Read the identifying information before looking at the purity percentage. A COA should state the compound name, lot or batch number, date of analysis and, ideally, the sample or product reference. The batch number on the report must match the batch number shown on the vial or associated product packaging.

This is the first filter because a generic report is not the same as batch-specific evidence. A document labelled only “BPC-157 99%” with no batch identifier cannot prove that your particular vial was tested. The same applies where a supplier displays one old report across multiple production runs.

Check that the listed peptide name is sufficiently precise. For example, a report should distinguish between closely related compounds, salt forms and esterified variants where relevant. A peptide sequence, molecular formula or molecular weight provides an additional layer of confirmation, particularly for buyers comparing technical documentation across suppliers.

Dates matter, but they require context. A COA date that predates the product by a reasonable manufacturing interval is not automatically a problem. A report that is years old, has no batch match or is repeatedly used for apparently new inventory deserves closer scrutiny.

How to read peptide COA purity results

The figure most buyers notice is purity, commonly reported as 99% or higher. That number is meaningful only when the COA explains how it was obtained. For peptides, reversed-phase high-performance liquid chromatography, generally written as RP-HPLC or HPLC, is a standard analytical method used to separate components in a sample.

An HPLC result may appear as an assay percentage, area percentage or chromatographic purity. These terms are related but not interchangeable. In many peptide COAs, purity is calculated from the relative area of the main peak against other detected peaks. If the primary peak represents 99.2% of the integrated chromatogram, the report may state 99.2% purity by HPLC area.

That is a strong quality indicator, but it is not a complete description of every possible characteristic of the material. HPLC primarily shows the separation profile of compounds detectable under that test method. It does not, by itself, confirm that the main peak is the intended peptide. That is why mass spectrometry should sit alongside chromatographic testing.

A reported purity of at least 99% is generally a useful benchmark for research-grade peptide material, provided the result is traceable and supported by appropriate identity testing. However, do not treat decimal precision as proof of superior quality in isolation. A clearly presented 99.1% result tied to a batch and full analytical evidence is more credible than a vague “99.9% purity” claim with no method, chromatogram or laboratory details.

Read the chromatogram, not just the headline number

Where a COA includes an HPLC chromatogram, look for one dominant, well-defined peak and relatively minor secondary peaks. The report should show retention time, detector wavelength where applicable, peak areas and an integration table.

Small peaks do not necessarily indicate poor material. Peptide synthesis can produce trace deletion sequences, residual starting material or related impurities. What matters is the overall profile, the stated threshold and whether the main peak accounts for the claimed purity.

Be cautious when the chromatogram is heavily cropped, lacks axes or integration data, or appears identical across supposedly different batches. A proper analytical trace should be readable enough to connect the visual profile with the stated numerical result.

Confirm identity with mass spectrometry

Mass spectrometry, often shown as MS, LC-MS or MALDI-TOF, helps confirm molecular identity by measuring mass-to-charge ratios. For a peptide COA, the observed molecular mass should align closely with the theoretical or expected molecular mass for the stated compound.

Peptides may display multiple charged ions in a mass spectrum, so the data will not always show one simple peak at the full molecular weight. This is normal. The report may list an observed mass, calculated mass and mass error, or display a spectrum with charge-state assignments. What you want to see is a clear agreement between the expected and measured result.

Mass spectrometry and HPLC answer different questions. HPLC supports the purity assessment by showing how much of the sample is represented by the principal component. MS supports identity by showing that the principal material has the expected molecular mass. A supplier claiming third-party tested, research-grade material should be able to provide evidence of both where those claims are made.

For compounds such as GHK-Cu, interpretation can be more nuanced because metal complexation and adduct formation may affect the observed spectrum. The right response is not to dismiss the report immediately, but to look for method-appropriate data and a coherent explanation of the expected mass profile.

Check the testing laboratory and report integrity

A reliable COA identifies the laboratory or analytical provider, the test date and the methods used. It may include an analyst signature, quality-control approval, instrument details, report number or laboratory contact information. Not every laboratory formats reports in the same way, but anonymous documents should carry less weight than documentation with accountable origins.

Third-party testing is valuable because it creates separation between the seller and the analytical result. Still, “third-party tested” should not end the assessment. Confirm that the report names the same compound and batch being offered, and that the methods match the claims made about purity and identity.

Look for basic document consistency. Compound name, batch number, sample description and dates should agree throughout the report. Spelling errors, altered typography, missing method details and inconsistent molecular weights are warning signs. One formatting quirk may be harmless; several inconsistencies warrant caution.

Know what a COA cannot tell you

A COA is essential evidence, but it is not a substitute for a complete quality system. It does not automatically verify transport conditions, storage history after release, sterility, endotoxin status, residual solvent levels or suitability for any particular application unless those tests are explicitly included.

This distinction matters for lyophilised peptides. An HPLC and MS report can support identity and purity at the time of testing, while correct storage and handling remain necessary to protect material integrity afterwards. Buyers should also avoid assuming that a purity COA demonstrates sterility. Sterility requires separate, specific testing and documentation.

The appropriate level of documentation depends on the compound and intended research context. For routine analytical comparison, batch-matched HPLC and MS may be the central requirements. For more sensitive laboratory work, you may need additional specifications such as peptide content, water content, microbial limits, residual solvents or endotoxin testing.

A practical COA review process

Before ordering, use a consistent sequence: match the batch number, verify the compound identity, review the HPLC purity result, check the chromatogram, compare observed and expected mass, then assess the laboratory details and report date. This takes minutes once you know what to look for and reduces the risk of judging quality from a single percentage.

At Aussie Peptide Labs, COA access, HPLC results and mass spectrometry data are positioned as part of the evidence buyers can use to assess batch quality. Documentation should support informed research purchasing, not replace careful handling or create assumptions beyond the tests actually reported.

A credible COA does not need extravagant design or inflated claims. It needs to make one clear case: this identified batch was analysed using stated methods, and the results support the specification. That standard is worth applying every time you evaluate peptide research material.